2026 CHIC | PrimeLink Bio to Share PLB-002 Clinical Progress and Latest Dual-Payload ADC Platform Advances

On March 23, 2026, Dr. Yin Mao, Founder and Chief Scientific Officer (CSO) of PrimeLink BioTherapeutics, will attend the 12th China Healthcare Investment Conference (CHIC). During the company presentation session from 3:30 PM to 5:45 PM, Dr. Yin will share updates on the clinical progress of PLB-002 (anti-Claudin 6 ADC) and the development and validation of the dual-payload ADC technology platform.

Dr. Yin is a postdoctoral fellow from Massachusetts General Hospital, Harvard Medical School, with over two decades of dedicated expertise in the ADC field. He holds dozens of international patents and possesses profound experience in drug discovery and process development. He previously served as a core inventor of the technology platform at a globally renowned ADC company, which was honored with the Best Technology Award at the World ADC Conference. In 2021, Dr. Yin returned to China and founded PrimeLink Bio, leading the team to independently develop the highly hydrophilic, modular ADC technology platform ENHANMIX^®, addressing the fundamental challenges of safety and drug resistance in traditional ADCs from the ground up.

Recently, PrimeLink Bio achieved a significant milestone: the successful completion of the first-in-human dosing for its core ADC pipeline candidate PLB-002, developed based on ENHANMIX^®. This ADC targets Claudin 6 and demonstrates exceptional potential in treating various solid tumors, including ovarian cancer and non-small cell lung cancer (NSCLC). Meanwhile, PrimeLink Bio is simultaneously advancing multiple novel pipeline programs. Notably, its dual-payload ADC platform has completed preliminary validation, featuring both high flexibility and excellent developability. The platform has shown efficacy in Enhertu-resistant and non-responsive models, and has also demonstrated significant synergistic therapeutic effects when expanded to other targets and indications.

About CHIC

The China Healthcare Investment Conference (CHIC) was founded in 2010 by leading healthcare investors from both domestic and international markets. Focused on cutting-edge sectors including biopharmaceuticals, innovative medical devices, and digital health, CHIC brings together top-tier investment institutions, listed pharmaceutical companies, and innovative enterprises. The conference facilitates in-depth exchanges on industry trends, investment and financing strategies, and technology commercialization, serving as a premium industry platform that bridges industry and capital to drive innovation and advancement in healthcare. The 12th CHIC will be held on March 23-24, 2026, at the Ritz-Carlton Shanghai, Pudong.

About PrimeLink Bio

PrimeLink Bio, founded in July 2021 by Dr. Yin Mao, is an innovative biopharmaceutical enterprise dedicated to developing next-generation antibody-drug conjugates (ADCs). Guided by the core philosophy of "tailoring the optimal ADC structure for each target," the company has independently developed a flexible, modular technology platform named ENHANMIX®. Featuring high hydrophilicity, compatibility, and flexibility, ENHANMIX® provides a novel approach to addressing safety and resistance challenges in ADC therapeutics.

Leveraging its innovative ENHANMIN®  and differentiated product pipeline, PrimeLink Bio has established a robust portfolio encompassing single-target ADCs and novel modalities such as bispecific ADCs and dual-payload ADCs. The company has secured investments from leading domestic and international investment institutions including Vertex Ventures, Fosun Pharma, Kaitai Capital, Longmen Capital, and Elikon Venture, raising cumulative financing exceeding RMB 200 million. PrimeLink Bio has also been honored with multiple prestigious awards, including the "Top 100 Chinese Pharmaceutical Innovation Value Discovery Companies 2022-2023," National "Technology-based SME," Shenzhen "Innovative SME," "Specialized and Innovative SME," and "Seed Unicorn Enterprise" designations, as well as "Outstanding Enterprise" at the 13th China Innovation and Entrepreneurship Competition.

Moving forward, PrimeLink Bio will continue to evolve its platform technology and advance its product pipeline to benefit cancer patients worldwide.